Should treatment of ALK‐positive anaplastic large cell lymphoma be stratified according to minimal residual disease?. Issue 6 (9th March 2021)

• Record Type: Journal Article
• Authors: Rigaud, Charlotte; Abbas, Rachid; Grand, David; Minard‐Colin, Véronique; Aladjidi, Nathalie; Buchbinder, Nimrod; Garnier, Nathalie; Plat, Geneviève; Couec, Marie‐Laure; Duplan, Mylène; Lambilliotte, Anne; Schmitt, Claudine; Leblanc, Thierry; Lamant, Laurence; Brugières, Laurence
• Is Part Of: Pediatric blood & cancer. Volume 68:Issue 6(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-03-09
• Subjects: ALCL -- anaplastic large cell lymphoma -- minimal residual disease -- MRD; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.28982
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: In anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma (ALK+ ALCL), positive minimal residual disease (MRD+) after the first chemotherapy course was proven of strong prognostic significance. We aimed to validate these results in 138 French patients. Eighty‐seven patients had a detectable minimal disseminated disease at diagnosis (MDD+). Early MRD assessment was performed in 33 of 87 patients and was positive in 18 and negative in 15 (MRD−). Three‐year progression‐free survival was significantly correlated with the MDD/MRD status: 81.1% in MDD−, 69.6% in MDD+/MRD−, and 15.2% in MDD+/MRD+ patients. In conclusion, we confirmed on an independent cohort that the MDD/MRD status has strong prognosis significance in ALK+ ALCL.